Loading
A phase 3 trial of Camrelizumab, Rivoceranib in hepatocellular carcinoma, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma is a phase 3 interventional study registered as NCT05320692 by Jiangsu HengRui Medicine Co., Ltd., with 423 participants enrolled, started 2022-08-09 and due to reach its primary completion in 2026-07-30. Interventions recorded: TACE+Camrelizumab+Apatinib mesylate, TACE. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Shares Rivoceranib (apatinib), Camrelizumab, Jiangsu Hengrui Pharmaceuticals, Anti-angiogenic therapy.
Shares Rivoceranib (apatinib), Camrelizumab, Jiangsu Hengrui Pharmaceuticals, Anti-angiogenic therapy.
Shares Rivoceranib (apatinib), Jiangsu Hengrui Pharmaceuticals, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Rivoceranib (apatinib), Camrelizumab, Jiangsu Hengrui Pharmaceuticals.
Shares Intermediate hepatocellular carcinoma (BCLC B), Anti-angiogenic therapy, Hepatocellular carcinoma, Small-molecule kinase inhibitors.
Shares Rivoceranib (apatinib), Jiangsu Hengrui Pharmaceuticals, Anti-angiogenic therapy, Hepatocellular carcinoma.
Shares Camrelizumab, Jiangsu Hengrui Pharmaceuticals, Immune checkpoint inhibitors.
Shares Rivoceranib (apatinib), Camrelizumab, Immune checkpoint inhibitors.